Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HROW Stock Forecast 2025-2026
$45.75
Current Price
$1.69B
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to HROW Price Targets
+105.5%
To High Target of $94.00
+51.9%
To Median Target of $69.50
+29.0%
To Low Target of $59.00
HROW Price Momentum
+9.5%
1 Week Change
+34.8%
1 Month Change
+16.4%
1 Year Change
+36.4%
Year-to-Date Change
-9.8%
From 52W High of $50.72
+119.4%
From 52W Low of $20.85
📊 TOP ANALYST CALLS
Did HROW Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Harrow Health is one of their latest high-conviction picks.
Latest HROW Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, HROW has a bullish consensus with a median price target of $69.50 (ranging from $59.00 to $94.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $45.75, the median forecast implies a 51.9% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HROW Analyst Ratings
8
Buy
0
Hold
0
Sell
HROW Price Target Range
Low
$59.00
Average
$69.50
High
$94.00
Current: $45.75
Latest HROW Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HROW.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 12, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $69.00 |
| Nov 12, 2025 | Ladenburg Thalmann | Jeffrey Cohen | Buy | Maintains | $66.00 |
| Oct 1, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Reiterates | $74.00 |
| Sep 29, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $64.00 |
| Sep 29, 2025 | Lake Street | Thomas Flaten | Buy | Maintains | $70.00 |
| Sep 29, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $63.00 |
| Sep 24, 2025 | BTIG | Thomas Shrader | Buy | Reiterates | $63.00 |
| Sep 23, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Sep 23, 2025 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $64.00 |
| Sep 23, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $70.00 |
| Aug 14, 2025 | BTIG | Thomas Shrader | Buy | Maintains | $63.00 |
| Aug 13, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $64.00 |
| Jul 11, 2025 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Initiates | $76.00 |
| Jun 10, 2025 | William Blair | Lachlan Brown | Outperform | Initiates | $N/A |
| May 12, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $60.00 |
| Apr 1, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Maintains | $65.00 |
| Mar 31, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $57.00 |
| Mar 18, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Reiterates | $57.00 |
| Feb 6, 2025 | HC Wainwright & Co. | Yi Chen | Buy | Initiates | $57.00 |
| Oct 4, 2024 | Craig-Hallum | Chase Knickerbocker | Buy | Maintains | $65.00 |
Harrow Inc. (HROW) Competitors
The following stocks are similar to Harrow Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Harrow Inc. (HROW) Financial Data
Harrow Inc. has a market capitalization of $1.69B with a P/E ratio of -93.4x. The company generates $250.04M in trailing twelve-month revenue with a -2.0% profit margin.
Revenue growth is +45.4% quarter-over-quarter, while maintaining an operating margin of +20.6% and return on equity of -9.6%.
Valuation Metrics
Market Cap
$1.69B
Enterprise Value
$1.87B
P/E Ratio
-93.4x
PEG Ratio
0.7x
Price/Sales
6.8x
Growth & Margins
Revenue Growth (YoY)
+45.4%
Gross Margin
+75.3%
Operating Margin
+20.6%
Net Margin
-2.0%
EPS Growth
+45.4%
Financial Health
Cash/Price Ratio
+4.6%
Current Ratio
2.7x
Debt/Equity
539.8x
ROE
-9.6%
ROA
+4.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Harrow Inc. (HROW) Business Model
About Harrow Inc.
What They Do
Develops and distributes innovative ophthalmic medicines.
Business Model
The company operates through a dynamic business model that includes both proprietary products and important generic formulations. By focusing on ophthalmology, it generates revenue by providing effective treatments for various eye conditions, ensuring affordability and accessibility to its products.
Additional Information
Harrow Inc. is headquartered in the United States and is committed to improving patient outcomes while enhancing the quality of life for consumers. The company's dedication to clinical excellence and its role in addressing critical market gaps make it a significant player in the healthcare and pharmaceutical sectors.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
382
CEO
Mr. Mark L. Baum J.D.
Country
United States
IPO Year
2007
Website
www.harrow.comHarrow Inc. (HROW) Latest News & Analysis
Latest News
Quick Summary
Penn Capital Management acquired 325,478 shares of Harrow for approximately $15.7 million in Q3, establishing a new position in the company.
Why It Matters
Penn Capital's significant investment in Harrow signals confidence in the company's prospects, potentially influencing market sentiment and attracting further interest from other investors.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Harrow (Nasdaq: HROW) will participate in two investor conferences: BTIG Ophthalmology Day on Dec 1 and Piper Sandler Healthcare Conference on Dec 2, both featuring fireside chats.
Why It Matters
Harrow's participation in key investor conferences signals active engagement with the investment community, potentially boosting visibility and investor confidence in its ophthalmic solutions.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Harrow (Nasdaq: HROW) has acquired Melt Pharmaceuticals, enhancing its portfolio with non-opioid sedation therapies. This move aims to improve patient outcomes in various medical settings.
Why It Matters
Harrow's acquisition of Melt Pharmaceuticals enhances its product offerings and market position, potentially driving revenue growth and improving patient outcomes, which could boost investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Harrow, Inc. (HROW) will hold its Q3 2025 earnings call on November 11, 2025, at 8:00 AM EST, featuring key executives and analysts from various financial firms.
Why It Matters
The earnings call provides insights into Harrow, Inc.'s financial performance and strategies, influencing stock price and investor sentiment based on management's outlook and analyst questions.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
In Q3 2025, total revenues rose 45% to $71.6 million, with GAAP net income at $1.0 million and adjusted EBITDA at $22.7 million. Cash and equivalents were $74.3 million as of September 30, 2025.
Why It Matters
Strong revenue growth of 45% and positive net income indicate robust business performance, enhancing investor confidence and potential for future profitability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Harrow, Inc. aims for $280M in revenue by 2025 and >$250M quarterly by Q4 2027, supported by acquisitions and partnerships, despite low profitability and modest cash reserves.
Why It Matters
Harrow, Inc.'s strong revenue growth targets and diverse product portfolio indicate potential for significant market gains, despite current profitability challenges. Management's experience boosts confidence in future performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About HROW Stock
What is Harrow Inc.'s (HROW) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Harrow Inc. (HROW) has a median price target of $69.50. The highest price target is $94.00 and the lowest is $59.00.
Is HROW stock a good investment in 2026?
According to current analyst ratings, HROW has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $45.75. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HROW stock?
Wall Street analysts predict HROW stock could reach $69.50 in the next 12 months. This represents a 51.9% increase from the current price of $45.75. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Harrow Inc.'s business model?
The company operates through a dynamic business model that includes both proprietary products and important generic formulations. By focusing on ophthalmology, it generates revenue by providing effective treatments for various eye conditions, ensuring affordability and accessibility to its products.
What is the highest forecasted price for HROW Harrow Inc.?
The highest price target for HROW is $94.00 from at , which represents a 105.5% increase from the current price of $45.75.
What is the lowest forecasted price for HROW Harrow Inc.?
The lowest price target for HROW is $59.00 from at , which represents a 29.0% increase from the current price of $45.75.
What is the overall HROW consensus from analysts for Harrow Inc.?
The overall analyst consensus for HROW is bullish. Out of 13 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $69.50.
How accurate are HROW stock price projections?
Stock price projections, including those for Harrow Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 4:55 PM UTC